Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
casopitant + ondansetron + dexamethasone
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of **casopitant** (an oral or intravenous neurokinin-1 receptor antagonist), **ondansetron** (a 5-HT3 receptor antagonist), and **dexamethasone** (a corticosteroid) is used as a three-drug antiemetic regimen for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy. - **Casopitant** antagonizes substance P at the neurokinin-1 receptor, blocking emetic signaling centrally. - **Ondansetron** blocks serotonin 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting emetic signaling peripherally and centrally. - **Dexamethasone** exerts anti-inflammatory and antiemetic effects, though its precise antiemetic mechanism is not fully understood, and may involve inhibition of prostaglandin synthesis and interaction with neurotransmitter pathways. Clinical studies have shown that this triple therapy improves control of CINV compared to two-drug regimens. Dose adjustments for dexamethasone are recommended due to pharmacokinetic interactions (casopitant increases dexamethasone exposure)[1][2][3][4].
- Brand names
- casopitant
- Other names
- casopitant + ondansetron + dexamethasone
02
Targets
GR (Glucocorticoid receptor)HTR3A (5-hydroxytryptamine receptor 3A)TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on casopitant + ondansetron + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on casopitant + ondansetron + dexamethasone.